Christina Kay
2021
In 2021, Christina Kay earned a total compensation of $246K as Co, Chief Executive Officer at Integrated Biopharma, a 7% increase compared to previous year.
Compensation breakdown
| Option Awards | $19,035 |
|---|---|
| Salary | $218,337 |
| Other | $8,657 |
| Total | $246,029 |
Kay received $218.3K in salary, accounting for 89% of the total pay in 2021.
Kay also received $19K in option awards and $8.7K in other compensation.
Rankings
In 2021, Christina Kay's compensation ranked 11,822nd out of 12,415 executives tracked by ExecPay. In other words, Kay earned more than 4.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 11,822 out of 12,415 | 5th |
Division Manufacturing | 5,217 out of 5,508 | 5th |
Major group Chemicals And Allied Products | 2,285 out of 2,378 | 4th |
Industry group Drugs | 2,027 out of 2,099 | 3rd |
Industry Pharmaceutical Preparations | 1,499 out of 1,549 | 3rd |
Source: SEC filing on October 27, 2021.
Kay's colleagues
We found three more compensation records of executives who worked with Christina Kay at Integrated Biopharma in 2021.
News
Integrated Biopharma CFO Dina Masi's 2024 pay rises 8% to $357K
October 28, 2024
Integrated Biopharma CFO Dina Masi's 2023 pay rises 10% to $330K
October 27, 2023
Integrated Biopharma CFO Dina Masi's 2022 pay rises 12% to $300K
October 27, 2022
Integrated Biopharma CFO Dina Masi's 2021 pay rises 6% to $268K
October 27, 2021
Integrated Biopharma CFO Dina Masi's 2019 pay rises 4% to $251K
October 28, 2019